Wall Street expects a year-over-year increase in earnings on higher revenues when Amneal Pharmaceuticals (AMRX) reports results for the quarter ended December 2024. While this widely-known consensus ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...

Amneal Pharmaceuticals (AMRX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...

BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), a biopharmaceutical company with a market capitalization of $2.4 billion and "GREAT" financial health according to InvestingPro ...

The FDA has approved a generic version of lenalidomide, a drug used to treat multiple myeloma and myelodysplastic syndromes, with availability set for Jan. 31, 2026.

In trading on Monday, shares of Amneal Pharmaceuticals Inc (Symbol: AMRX) crossed below their 200 day moving average of $7.76, changing hands as low as $7.68 per share. Amneal Pharmaceuticals Inc ...

The approvals provide therapies for dementia, oncology and gastrointestinal disease. Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults ...

Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today ...